← Back to Screener
Longeveron Inc. Common Stock (LGVN)
Price$1.04
Favorite Metrics
Price vs S&P 500 (26W)26.62%
Price vs S&P 500 (4W)2.75%
Market Capitalization$25.59M
All Metrics
Book Value / Share (Quarterly)$0.25
P/TBV (Annual)3.18x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-0.63%
Cash Flow / Share (Quarterly)$-0.84
Price vs S&P 500 (YTD)113.25%
Gross Margin (TTM)66.97%
Net Profit Margin (TTM)-1893.58%
EPS (TTM)$-1.31
10-Day Avg Trading Volume1.01M
EPS Excl Extra (TTM)$-1.31
Revenue Growth (5Y)-26.60%
EPS (Annual)$-1.29
ROI (Annual)-400.07%
Gross Margin (Annual)66.97%
Net Profit Margin (5Y Avg)-1685.60%
Cash / Share (Quarterly)$0.20
Revenue Growth QoQ (YoY)-39.47%
ROA (Last FY)-221.26%
Revenue Growth TTM (YoY)-49.87%
EBITD / Share (TTM)$-1.22
ROE (5Y Avg)-185.61%
Operating Margin (TTM)-1942.20%
Cash Flow / Share (Annual)$-0.84
P/B Ratio4.51x
P/B Ratio (Quarterly)1.90x
Net Income / Employee (Annual)$-1
EV / Revenue (TTM)17.46x
Net Interest Coverage (TTM)-4260.25x
ROA (TTM)-143.21%
EPS Incl Extra (Annual)$-1.29
Current Ratio (Annual)1.33x
Quick Ratio (Quarterly)1.17x
3-Month Avg Trading Volume3.93M
52-Week Price Return-21.99%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.15
P/S Ratio (Annual)21.35x
Asset Turnover (Annual)0.12x
52-Week High$1.83
Operating Margin (5Y Avg)-1686.28%
EPS Excl Extra (Annual)$-1.29
CapEx CAGR (5Y)17.87%
26-Week Price Return35.37%
Quick Ratio (Annual)1.17x
13-Week Price Return97.27%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)1.33x
Enterprise Value$20.934
Revenue / Share Growth (5Y)-53.11%
Asset Turnover (TTM)0.08x
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-1893.58%
Cash / Share (Annual)$0.20
3-Month Return Std Dev160.42%
Gross Margin (5Y Avg)52.55%
Net Income / Employee (TTM)$-1
ROE (Last FY)-400.07%
Net Interest Coverage (Annual)-73.31x
EPS Basic Excl Extra (Annual)$-1.29
Receivables Turnover (TTM)12.76x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-1.31
Receivables Turnover (Annual)12.76x
ROI (TTM)-199.79%
P/S Ratio (TTM)21.35x
Pretax Margin (5Y Avg)-1685.60%
Revenue / Share (Annual)$0.07
Tangible BV / Share (Annual)$0.15
Price vs S&P 500 (52W)-57.08%
Year-to-Date Return117.39%
5-Day Price Return-1.79%
EPS Normalized (Annual)$-1.29
ROA (5Y Avg)-113.92%
Net Profit Margin (Annual)-1893.58%
Month-to-Date Return5.77%
Cash Flow / Share (TTM)$-0.89
EBITD / Share (Annual)$-1.22
Operating Margin (Annual)-1942.20%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-185.61%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-1.31
P/TBV (Quarterly)3.18x
P/B Ratio (Annual)1.90x
Pretax Margin (TTM)-1893.58%
Book Value / Share (Annual)$0.25
Price vs S&P 500 (13W)94.41%
Beta-0.14x
Revenue / Share (TTM)$0.05
ROE (TTM)-199.79%
52-Week Low$0.47
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.13
4.13
4.13
4.13
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
LGVNLongeveron Inc. Common Stock | 21.35x | -49.87% | 66.97% | — | $1.04 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Longeveron Inc is a clinical-stage biotechnology company developing Lomecel-B, an allogeneic stem cell therapy designed to promote tissue repair and regeneration in aging-related and life-threatening diseases. The company is advancing three pipeline programs targeting Hypoplastic Left Heart Syndrome, Alzheimer's disease, and aging-related frailty.